DK374087A - Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne - Google Patents

Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne

Info

Publication number
DK374087A
DK374087A DK374087A DK374087A DK374087A DK 374087 A DK374087 A DK 374087A DK 374087 A DK374087 A DK 374087A DK 374087 A DK374087 A DK 374087A DK 374087 A DK374087 A DK 374087A
Authority
DK
Denmark
Prior art keywords
cells
antibodies
procedure
expression vectors
factor viii
Prior art date
Application number
DK374087A
Other languages
English (en)
Other versions
DK374087D0 (da
Inventor
Ooyen Albert Johannes Jose Van
Peter Michael Andreoli
Mourik Jan Aart Van
Hans Pannekoek
Original Assignee
Gist Brocades Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868617594A external-priority patent/GB8617594D0/en
Priority claimed from GB868630699A external-priority patent/GB8630699D0/en
Application filed by Gist Brocades Nv filed Critical Gist Brocades Nv
Publication of DK374087D0 publication Critical patent/DK374087D0/da
Publication of DK374087A publication Critical patent/DK374087A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK374087A 1986-07-18 1987-07-17 Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne DK374087A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868617594A GB8617594D0 (en) 1986-07-18 1986-07-18 Preparation of biologically active proteins
GB868630699A GB8630699D0 (en) 1986-12-23 1986-12-23 Preparation of biologically active proteins

Publications (2)

Publication Number Publication Date
DK374087D0 DK374087D0 (da) 1987-07-17
DK374087A true DK374087A (da) 1988-01-19

Family

ID=26291059

Family Applications (1)

Application Number Title Priority Date Filing Date
DK374087A DK374087A (da) 1986-07-18 1987-07-17 Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne

Country Status (9)

Country Link
EP (1) EP0253455A1 (da)
JP (1) JPS63313587A (da)
AU (1) AU620315B2 (da)
DK (1) DK374087A (da)
FI (1) FI873162A (da)
IL (1) IL83192A (da)
NO (1) NO872932L (da)
NZ (1) NZ221119A (da)
PT (1) PT85349B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5543145A (en) * 1984-09-17 1996-08-06 Baxter International, Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
EP0218692A4 (en) * 1985-04-11 1988-03-22 Childrens Medical Center VON WILLEBRAND FACTOR.
US5278066A (en) * 1985-08-09 1994-01-11 Gist-Brocades Nv Molecular cloning and expression of gene encoding lipolytic enzyme
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US5830735A (en) * 1987-03-06 1998-11-03 Gist-Brocades Nv Method for producing lipolytic enzymes using transformed Pseudomonas
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU627150B2 (en) * 1987-06-12 1992-08-20 Immuno Ag Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
EP0294910B1 (en) * 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) * 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
GB2214508A (en) * 1988-01-27 1989-09-06 Bayer Ag Plasmid vector for the efficient expression of foreign genes fused with newly conceived transcriptional and translational signal sequences.
CA2030554C (en) * 1989-06-29 2001-08-28 Wilhelmus J. Quax Mutant microbial .alpha.-amylases with increased thermal, acid, and/or alkaline stability
CA2067158A1 (en) * 1989-09-14 1991-03-15 R. Alan Hardwick Method and useful apparatus for preparing pharmaceutical compositions
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
US6500646B1 (en) * 1996-12-27 2002-12-31 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs
US20050079573A1 (en) 1998-12-23 2005-04-14 Danisco A/S Proteins
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
NZ524814A (en) 2000-09-21 2004-08-27 Basf Ag Talaromyces xylanases
BR0115998B1 (pt) 2000-12-07 2015-02-18 Dsm Ip Assets Bv Método para a prevenção ou redução de turvação em uma bebida, bem como bebidas obteníveis a partir de dito método.
DK1339837T3 (da) 2000-12-07 2008-06-09 Dsm Ip Assets Bv Prolyl-endoprotease fra Aspergillus Niger
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
EP1418810A4 (en) 2001-08-03 2006-08-02 Us Gov Health & Human Serv TREATMENT OF HEMOPHILIA ORAL
EP1511835B9 (en) 2002-06-07 2015-02-25 DSM IP Assets B.V. Improved method for the prevention or reduction of haze in beverages
TWI328612B (en) 2002-07-25 2010-08-11 Dsm Ip Assets Bv Genes and their encoded polypeptides involved in the biosynthetic pathway of vitamin b12, vectors and host cells comprising the genes, and process for producing vitamin b12
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
ES2755775T3 (es) 2005-11-28 2020-04-23 Dsm Ip Assets Bv Preparación de enzima que produce un sabor puro
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
ES2492469T3 (es) 2007-02-20 2014-09-09 Dsm Ip Assets B.V. Nueva sialidasa
JP2010521188A (ja) 2007-03-22 2010-06-24 ディーエスエム アイピー アセッツ ビー．ブイ． 新規リシルオキシダーゼ
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
WO2011101339A2 (en) 2010-02-18 2011-08-25 Dsm Ip Assets B.V. Fermentation broth and filtration filter cake and uses thereof
WO2012007446A1 (en) 2010-07-13 2012-01-19 Dsm Ip Assets B.V. Use of a mutarotase in the production of dried powders
WO2012007445A1 (en) 2010-07-13 2012-01-19 Dsm Ip Assets B.V. Mutarotase in crystallization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586402T3 (de) * 1984-01-12 2004-12-23 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Proteinzusammensetzung mit Koagulations-wirkung und Verfahren zu ihrer Herstellung.
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta

Also Published As

Publication number Publication date
EP0253455A1 (en) 1988-01-20
PT85349A (en) 1987-08-01
PT85349B (pt) 1990-04-30
AU620315B2 (en) 1992-02-20
JPS63313587A (ja) 1988-12-21
DK374087D0 (da) 1987-07-17
FI873162A (fi) 1988-01-19
NZ221119A (en) 1990-08-28
NO872932D0 (no) 1987-07-14
IL83192A (en) 1992-11-15
AU7575487A (en) 1988-01-21
NO872932L (no) 1988-01-19
IL83192A0 (en) 1987-12-31
FI873162A0 (fi) 1987-07-17

Similar Documents

Publication Publication Date Title
DK374087D0 (da) Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne
DK110885D0 (da) Nucleinsyre-proteinkonjugater, disses anvendelse samt fremgangsmaade til fremstilling heraf
DE3587549D1 (de) Ergänzungstestverfahren von proteine bindenden enzymen.
DE3888921D1 (de) Polypeptide.
NO881658L (no) Biofunksjonelle proteiner.
GB8501473D0 (en) Cloned dna sequences
NO882226D0 (no) Fibrinolytiske proteiner.
NO885013D0 (no) FremgangsmŸte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppnŸdd ved fremgangsmŸten.
NO174970C (no) Rekombinant DNA, rekombinant DNA-vektor samt vertscelle
DK490888A (da) Immunoassay og biologiske konstruktioner til anvendelse ved denne
DK41590A (da) Forbedrede protein c-molekyler samt fremgangsmaade til fremstilling og aktivering af samme
NO881548L (no) Genteknologisk fremgangsmaate for fremstilling av polypeptider.
DK723488A (da) Fremgangsmaade til rekombinant udtrykkelse af zymogene former af humant protein c samt vektorer, dna-forbindelser og transformanter til brug ved fremgangsmaaden
DK533087A (da) Anthracyklinglykosider, deres fremstilling, mellemprodukter deraf samt praeparater indeholdende disse og deres anvendelse
NO871137L (no) Ikke-betennelsesfremkallende hyaluronsyrefraksjon og fremgangsmaate for fremstilling av denne.
NO169819C (no) Fremgangsmaate for fremstilling av hybrid polypeptid og dna-molekyl for bruk i denne
DK161487D0 (da) Alfa-interferon-analoge og fremgangsmaade til fremstilling deraf samt udtrykkelsesvektorer og vaertsorganismer til anvendelse ved fremgangsmaaden.
DK341485D0 (da) Faktor viii-r protein og fremgangsmaade til fremstilling heraf ved rekombinant-dna-syntese
DK623188D0 (da) Fremgangsmaade til inkubation af rekombinante proteinekspressionsceller
NO178036C (no) Fremgangsmåte for fremstilling av fusjonsproteiner, genstruktur, vektorer streptomycetceller og fusjonsproteinene
DE3780855D1 (de) Zellkultur-methode.
NO892948L (no) Modifiserte proteiner.
DK116487D0 (da) Fremgangsmaade til eksponering af en epitop i et protein med bestemt polypeptidstruktur, samt vektorer til brug ved fremgangsmaaden, hybridproteiner omfattende epitopen, og anvendelse af hybridproteinet ved diagnoser.
DK279587A (da) Fremgangsmaade til fremstilling af mikrobaerere for dyrkning af celler, og mikrobaerere fremstillet ved denne fremgangsmaade
DE3773651D1 (de) Probenladegeraet.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment